AUROBINDO PHARMA LTDAtualizado Aurobindo Pharma - Facing resistance from 52 week high - Level
#AUROPHARMA is treading near to 52-week high zone and since two treading session is closing in red near to 840 level. Level 846 is a strong resistance for stock.Stock is close crossing above Upper bolinger band from above.
Showing Mix result in Technical Parameter:
CCI iin overbought zone but treading down
MACD is treading UP above 0
RSI is near and parallel to overbought zone
Stoch iin overbought zone
MFI is treading down
ATR is touching bottom
New Short position
----------------------------------------------------------
Support : 800 and 780
Breakdown : 826
LTP : 836.55
Breakout : 846
Short Target : 860 and 880
----------------------------------------------------------
Positive & Negative Point:
1) Very bullish in Daily/Weekly/monthly chart
2) NR7 and Doji candle
3) Close within 52-week high
----------------------------------------------------------
(Disclaimer: This is only for educational purpose and paper treading.)
Showing Mix result in Technical Parameter:
CCI iin overbought zone but treading down
MACD is treading UP above 0
RSI is near and parallel to overbought zone
Stoch iin overbought zone
MFI is treading down
ATR is touching bottom
New Short position
----------------------------------------------------------
Support : 800 and 780
Breakdown : 826
LTP : 836.55
Breakout : 846
Short Target : 860 and 880
----------------------------------------------------------
Positive & Negative Point:
1) Very bullish in Daily/Weekly/monthly chart
2) NR7 and Doji candle
3) Close within 52-week high
----------------------------------------------------------
(Disclaimer: This is only for educational purpose and paper treading.)
Trade ativo
Breakdown completed.Trade fechado: objetivo atingido
Hit the support target 800 and closed on same level.
Aviso legal
As informações e publicações não devem ser e não constituem conselhos ou recomendações financeiras, de investimento, de negociação ou de qualquer outro tipo, fornecidas ou endossadas pela TradingView. Leia mais em Termos de uso.